medigraphic.com
ISSN 1561-302X (Impreso)

2022, Número 1

<< Anterior Siguiente >>

Rev cubana med 2022; 61 (1)


La dipeptidil peptidasa 4 y su función frente a la COVID-19

Poma CM, Bardales ZV

Idioma: Español
Referencias bibliográficas: 33
Paginas: 1-9
Archivo PDF: 255.09 Kb.


RESUMEN

Ante la aparición de un “nuevo virus” en la ciudad de Wuhan-China, llamado SARS-CoV-2, causante del conocido síndrome agudo respiratorio severo (COVID-19), muchos de científicos tratan de hallar una solución contra el virus que ha ocasionado una pandemia. En esta búsqueda, se encontró a una glicoproteína de transmembrana llamada dipeptidil peptidasa 4 o DPP-4 presente en la superficie de diferentes tipos de células y diana en la infección por el MERS-Co-V que abre una esperanza al sospechar que la DPP-4 puede ser un blanco en diferentes coronavirus al servir como estrategia terapéutica.
A ello se suman resultados que encuentran la DPP-4 elevada en pacientes con complicaciones graves ante COVID-19, lo que puede ser un posible marcador de gravedad. Sin embargo, aún existe poco énfasis en la identificación y asociación de esta glicoproteína a la COVID-19. Para ello, se realizó una revisión bibliográfica sobre los aspectos más significativos de la Dipeptidil Peptidasa 4 y su función frente a la COVID-19.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Papadokostaki E, Tentolouris N, Liberopoulos E. COVID-19 and diabetes: What does the clinician need to know? Primary Care Diabetes. 2020[acceso: 10/11/2020];14(5):558-63. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332931/

  2. Hamid S, Mir M, Rohela G. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes and New Infections. 2020[acceso: 10/10/2020];35:100679. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171518/

  3. Solerte S, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP-4) inhibition in COVID-19. Acta Diabetológica. 2020[acceso: 11/11/2020];57(7):779-83. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32506195/

  4. Phyu Khin P, Cha S, Jun H, Lee J. A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression. Medical Hypotheses. 2020[acceso: 01/12/2020];144:110186. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427591/

  5. Devaux C, Rolain J, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection. 2020[acceso: 13/10/2020];53(3):425-35. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32414646/

  6. Barchetta I, Cavallo M, Baroni M. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. Diabetes Research and Clinical Practice. 2020 May [cited 2020 Oct 11];163:108165. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177127/

  7. Pitocco D, Tartaglione L, Viti L, Di Leo M, Pontecorvi A, Caputo S. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?. Diabetes Research and Clinical Practice. 2020[acceso: 12/10/2020];163:108162. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32335097/

  8. Iacobellis G. COVID-19 and diabetes: Can DPP-4 inhibition play a role? Diabetes Research and Clinical Practice. 2020[acceso: 14/10/2020];162:108125. Disponible en: Disponible en: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30375-2/fulltext

  9. Dalan R. Is DPP-4 inhibition a comrade or adversary in COVID-19 infection. Diabetes Research and Clinical Practice. 2020[acceso: 20/10/2021];164:108216. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235575/

  10. Morin N. Response to COVID-19 and diabetes: Can DPP-4 inhibition play a role? - GLP-1 might play one too. Diabetes Research and Clinical Practice. 2020[acceso: 28/10/2020];164:108160. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175913/

  11. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology. 2020[acceso: 30/11/2020];8(9):782-92. Disponible en: Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30238-2/fulltext

  12. Yadav R, Aggarwal S, Singh A. SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020[acceso: 30/11/2020];14(5):1355-60. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372253/

  13. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and other human coronaviruses. Trends in Immunology. 2020[acceso: 15/11/2020];41(5):355-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32249063/

  14. Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization. Cytokine & Growth Factor Reviews. 2020[acceso: 22/12/2020];54:32-42. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328575/

  15. Rodríguez Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global-Travel and the 2019 novel coronavirus. Travel Medicine and Infectious Disease. 2020[acceso: 20/11/2020];33:101578. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32044389/

  16. Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020[acceso: 21/11/2020]; 551:1-9. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0042682220301720

  17. Lahiri D, Mondal R, Deb S, Bandyopadhyay D, Shome G, Sarkar S, et al. Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020[acceso: 31/12/2020];14(5):1053-60. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1871402120302320

  18. Pérez Martínez P. Resolviendo una de las piezas del puzle: COVID-19 y diabetes tipo 2. Rev Clin Esp. 2020;220(8):507-10. DOI: https://doi.org/10.1016/j.rce.2020.05.003

  19. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Research and Clinical Practice. 2020[acceso: 28/11/2020];163:108146. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151403/#:~:text=Although%20there%20is%20no%20dearth,one%20drug%20over%20the%20other

  20. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice. 2020[acceso: 20/11/2020];162:108142. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144611/

  21. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet Diabetes & Endocrinology. 2020[acceso: 30/11/2020];8(6):546-50. Disponible en: Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30152-2/fulltext

  22. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of Infection and Public Health. 2020[acceso: 30/12/2020];13(10):1373-80. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1876034120305311

  23. Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerging Microbes & Infections. 2020[acceso: 21/11/2020];9(1):601-4. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32178593/

  24. Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R, Pozzilli P. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice. 2021[acceso: 18/11/2020];171:108444. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32946854/

  25. Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Medical Hypotheses. 2020[acceso: 31/10/2020];143:110111. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0306987720313128

  26. Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, et al. Antibody-dependent enhancement of coronavirus. International Journal of Infectious Diseases. 2020[acceso: 18/11/2020];100:483-9. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1201971220307311

  27. Montagnani A, Filippo P, Gnerre P, Manfellotto D. Diabetes and COVID-19: Experience from the frontline of Internal Medicine wards in Italy. Research Gate. Elsevier. 2020[acceso: 18/11/2020]. Disponible en: Disponible en: https://www.researchgate.net/publication/343044091_Diabetes_and_CoViD-19_Experience_from_the_frontline_of_Internal_Medicine_wards_in_Italy

  28. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003[acceso: 28/10/2020];58(8):686-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/12885985/

  29. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases. 2016[acceso: 28/10/2020];49:129-33. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/27352628/

  30. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020[acceso: 22/11/2020] 323(18):1715-76. Disponible en: Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2763667

  31. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? Journal of Diabetes and its Complications. 2020[acceso: 11/12/2020];34(12):107723. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1056872720304980

  32. Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? Diabetes Research and Clinical Practice. 2020[acceso: 20/11/2020];163:108151. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162752/

  33. Gentile S, Mambro A, Strollo F. Parallel epidemics, or nearly so: Certainties and uncertainties about SARS-CoV-2 in Italy. Diabetes Research and Clinical Practice. 2020[acceso: 31/10/2020];164:108195. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214347/




2020     |     www.medigraphic.com